Close

Ayala Pharmaceuticals Inc. (AYLA) Reports Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102

Go back to Ayala Pharmaceuticals Inc. (AYLA) Reports Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102

Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors

July 5, 2022 8:00 AM EDT

- Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks -

- Favorable safety results observed: AL102 was well tolerated -

- Additional data to be submitted for presentation at a medical conference in 2H 2022 -

REHOVOT, Israel & WILMINGTON, Del., July 05, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology... More